Zai Lab (NASDAQ:ZLAB) Hits New 1-Year Low – Should You Sell?

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $19.42 and last traded at $19.6960, with a volume of 53694 shares changing hands. The stock had previously closed at $19.88.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ZLAB shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zai Lab in a research report on Wednesday, October 8th. Citigroup reaffirmed a “buy” rating and set a $69.00 target price (up from $66.00) on shares of Zai Lab in a report on Monday, August 11th. Finally, Jefferies Financial Group initiated coverage on shares of Zai Lab in a report on Monday, August 25th. They issued a “buy” rating and a $52.00 price target for the company. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $56.35.

Zai Lab Price Performance

The firm has a market capitalization of $2.19 billion, a PE ratio of -9.60 and a beta of 1.07. The firm has a fifty day moving average price of $26.61 and a 200 day moving average price of $31.94.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.05). Zai Lab had a negative return on equity of 27.32% and a negative net margin of 49.68%.The company had revenue of $116.10 million for the quarter, compared to analyst estimates of $150.24 million. Zai Lab has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.

Insiders Place Their Bets

In other news, insider Joshua L. Smiley bought 10,000 shares of the business’s stock in a transaction on Wednesday, September 10th. The shares were bought at an average cost of $28.91 per share, with a total value of $289,100.00. Following the purchase, the insider directly owned 86,604 shares in the company, valued at $2,503,721.64. This trade represents a 13.05% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 4.96% of the company’s stock.

Institutional Investors Weigh In On Zai Lab

Several hedge funds have recently bought and sold shares of ZLAB. Acadian Asset Management LLC acquired a new position in shares of Zai Lab in the 1st quarter valued at about $1,073,000. Raymond James Financial Inc. grew its position in Zai Lab by 219.6% during the first quarter. Raymond James Financial Inc. now owns 125,967 shares of the company’s stock valued at $4,552,000 after purchasing an additional 86,547 shares in the last quarter. Invesco Ltd. lifted its position in Zai Lab by 23.0% in the 1st quarter. Invesco Ltd. now owns 54,544 shares of the company’s stock worth $1,971,000 after buying an additional 10,204 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Zai Lab during the 1st quarter valued at $297,000. Finally, MY.Alpha Management HK Advisors Ltd purchased a new position in shares of Zai Lab during the 1st quarter valued at $8,643,000. 41.65% of the stock is owned by hedge funds and other institutional investors.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.